Posts tagged CRISPR-Cas9
Marc Becker joins CRISPR Therapeutics as CFO

Closely-held CRISPR Therapeutics has appointed Marc Becker as CFO to further support the company’s efforts to develop game-changing drugs derived from its proprietary CRISPR-Cas9 gene-editing technology platform.

Mr. Becker is a seasoned executive who brings more than 20 years of experience in commercial, operational and corporate finance and a deep understanding of the global biopharmaceutical industry.

Read More